Nectar Lifesciences Ltd (NSE: NECLIFE, BSE: 532649) is a Chandigarh-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹205 Cr, it ranks #2,648 by market cap among the 6,137 Indian listed companies on FinBizNet, and #56 of 86 in Medicinal Chemicals and Botanical Products. At ₹10.28 (as of 25 Oct 2026), the share price is 54.1% below its 52-week high of ₹22.40 and 10.5% above its 52-week low of ₹9.30. The share price is down 25.2% over one year and down 0.2% over three months.
| Current Price | ₹10.28 |
|---|---|
| Market Cap | ₹205 Cr |
| NSE Symbol | NECLIFE |
| BSE Code | 532649 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | -4.2 |
| Return on Equity | -7.46% |
| Return on Assets | -5.21% |
| 52-Week Range | ₹9.30 – ₹22.40 |
| 1-Year Price Change | -25.2% |
| 3-Month Price Change | -0.2% |
| Beta (1Y) | 0.98 |
| Dividend Yield | 0.00% |
| Headquarters | Chandigarh |
| Website | www.neclife.com |
| Revenue | ₹0 Cr |
|---|---|
| Net Profit | ₹-16 Cr |
| Net Margin | -157200.0% |
| EPS (Basic) | ₹-0.81 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Nectar Lifesciences Limited manufactures, distributes, markets and sells pharmaceutical products in India and internationally. The company offers cephalosporins, includes pharmaceutical ingredients and intermediates comprising cefixime, cefuroxime axetil amorphous, cefuroxime axetil crystalline, cefotaxime sodium, ceftriaxone sodium, cefixime trihydrate, cefuroxime axetil, cefpodoxime proxetil and sterile, cefprozil, cefdinir, cefuroxime sodium, cefazolin sodium, ceftazidime pentahydrate, and cefepime +Arginine. It also provides contract manufacturing for finished dosage forms, such as tablets, capsules, dry powder oral suspensions, and granules and injectable for cephalosporins. In addition, the company offers menthol and pearl capsules. Nectar Lifesciences Limited was incorporated in 1995 and is headquartered in Chandigarh, India.
1. Pharmaceutical Business-This segment operates as an integrated pharmaceutical company. It manufactures active pharmaceutical ingredients and formulations.
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,21,995 Cr | 36.4 | 14.72% | ₹15,300 Cr | +5.4% |
| Zydus Lifesciences Ltd | ₹1,12,020 Cr | 22.2 | 18.32% | ₹8,017 Cr | +14.7% |
| Laurus Labs Ltd | ₹1,11,310 Cr | 125.3 | 17.74% | ₹2,026 Cr | +125.7% |
| Cipla Limited | ₹1,07,048 Cr | 27.6 | 11.74% | ₹7,119 Cr | -14.7% |
| Dr.Reddys Lab | ₹1,02,611 Cr | 24.1 | 11.52% | ₹8,698 Cr | -0.9% |
| Aurobindo Pharma Ltd. | ₹95,910 Cr | 26.8 | 9.93% | ₹9,150 Cr | +41.7% |
| Mankind Pharma | ₹93,977 Cr | 48.7 | 12.45% | ₹4,031 Cr | -9.9% |
| Lupin Ltd | ₹89,426 Cr | 16.6 | 26.91% | ₹8,277 Cr | -1.1% |
| Nectar Lifesciences Ltd | ₹205 Cr | -4.2 | -7.46% | ₹0 Cr | -25.2% |
Listed by market capitalisation. Ratios are shown for context only.
Nectar Lifesciences Ltd is trading at ₹10.28, with a market capitalisation of ₹205 Cr.
Nectar Lifesciences Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Nectar Lifesciences Ltd has a P/E of -4.2 and a return on equity of -7.46%.
Nectar Lifesciences Ltd is listed on the NSE under the symbol NECLIFE and on the BSE under the scrip code 532649.
Nectar Lifesciences Ltd's share price is down 25.2% over one year and down 0.2% over three months. Its 52-week range is ₹9.30 to ₹22.40.
In Q1 FY27, Nectar Lifesciences Ltd reported revenue of ₹0 Cr and net profit of ₹-16 Cr, with basic EPS of ₹-0.81 (consolidated, parsed from the company's exchange filing).
Data as of 25 Oct 2026. Descriptive market data only — not investment advice.